Does the media favor AMN or OMCL?

In the previous week, AMN Healthcare Services had 3 more articles in the media than Omnicell. MarketBeat recorded 5 mentions for AMN Healthcare Services and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.58 beat AMN Healthcare Services' score of 0.06 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor WST or OMCL?

In the previous week, West Pharmaceutical Services had 9 more articles in the media than Omnicell. MarketBeat recorded 11 mentions for West Pharmaceutical Services and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.58 beat West Pharmaceutical Services' score of 0.42 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MMED or OMCL?

In the previous week, MiniMed Group had 5 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for MiniMed Group and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.58 beat MiniMed Group's score of 0.17 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HAE or OMCL?

Haemonetics has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 3.99 $97.31M $2.04 57.32 Omnicell $1.25B 1.33 $2.05M $0.84 43.26

Is HAE or OMCL more profitable?

Haemonetics has a net margin of 7.12% compared to Omnicell's net margin of 3.13%. Haemonetics' return on equity of 27.55% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% Omnicell 3.13% 5.66% 3.57%

Does the media favor HAE or OMCL?

In the previous week, Haemonetics had 6 more articles in the media than Omnicell. MarketBeat recorded 8 mentions for Haemonetics and 2 mentions for Omnicell. Haemonetics' average media sentiment score of 0.65 beat Omnicell's score of 0.58 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TFX or OMCL?

Omnicell has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teleflex $2.25B 2.45 -$905.64M -$23.29 N/A Omnicell $1.25B 1.33 $2.05M $0.84 43.26

Is TFX or OMCL more profitable?

Omnicell has a net margin of 3.13% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Teleflex -39.67% 11.93% 5.44% Omnicell 3.13% 5.66% 3.57%

Does the media favor TFX or OMCL?

In the previous week, Omnicell had 1 more articles in the media than Teleflex. MarketBeat recorded 2 mentions for Omnicell and 1 mentions for Teleflex. Omnicell's average media sentiment score of 0.58 beat Teleflex's score of -0.15 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omnicell (OMCL) Competitors

$37.10 +0.76 (+2.09%)

Closing price 04:00 PM Eastern

Extended Trading

$37.10 0.00 (0.00%)

As of 07:30 PM Eastern

Compare

OMCL vs. AMN, WST, MMED, HAE, and TFX

Should you buy Omnicell stock or one of its competitors? Omnicell's main competitors and comparable companies include AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), MiniMed Group (MMED), Haemonetics (HAE), and Teleflex (TFX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Omnicell compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Omnicell has a net margin of 3.13% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	3.06%	19.92%	5.93%
Omnicell	3.13%	5.66%	3.57%

Omnicell has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.61	-$95.70M	$2.68	16.06
Omnicell	$1.25B	1.33	$2.05M	$0.84	43.26

In the previous week, AMN Healthcare Services had 3 more articles in the media than Omnicell. MarketBeat recorded 5 mentions for AMN Healthcare Services and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.58 beat AMN Healthcare Services' score of 0.06 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services presently has a consensus target price of $36.50, suggesting a potential downside of 15.18%. Omnicell has a consensus target price of $57.86, suggesting a potential upside of 59.21%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

AMN Healthcare Services has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Summary

Omnicell beats AMN Healthcare Services on 10 of the 16 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

West Pharmaceutical Services currently has a consensus target price of $391.17, suggesting a potential downside of 0.70%. Omnicell has a consensus target price of $57.86, suggesting a potential upside of 59.21%. Given Omnicell's higher possible upside, analysts clearly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.86
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

West Pharmaceutical Services has a net margin of 16.98% compared to Omnicell's net margin of 3.13%. West Pharmaceutical Services' return on equity of 20.11% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.98%	20.11%	14.83%
Omnicell	3.13%	5.66%	3.57%

West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

In the previous week, West Pharmaceutical Services had 9 more articles in the media than Omnicell. MarketBeat recorded 11 mentions for West Pharmaceutical Services and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.58 beat West Pharmaceutical Services' score of 0.42 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

West Pharmaceutical Services has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.07B	9.02	$493.70M	$7.81	50.44
Omnicell	$1.25B	1.33	$2.05M	$0.84	43.26

Summary

West Pharmaceutical Services beats Omnicell on 12 of the 16 factors compared between the two stocks.

How does Omnicell compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

MiniMed Group currently has a consensus price target of $24.25, indicating a potential upside of 36.24%. Omnicell has a consensus price target of $57.86, indicating a potential upside of 59.21%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.68
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

97.7% of Omnicell shares are owned by institutional investors. 0.0% of MiniMed Group shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Omnicell has a net margin of 3.13% compared to MiniMed Group's net margin of 0.00%. Omnicell's return on equity of 5.66% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Omnicell	3.13%	5.66%	3.57%

In the previous week, MiniMed Group had 5 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for MiniMed Group and 2 mentions for Omnicell. Omnicell's average media sentiment score of 0.58 beat MiniMed Group's score of 0.17 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.22B	1.55	-$333M	-$0.68	N/A
Omnicell	$1.25B	1.33	$2.05M	$0.84	43.26

Summary

Omnicell beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

How does Omnicell compare to Haemonetics?

Haemonetics (NYSE:HAE) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Haemonetics has a net margin of 7.12% compared to Omnicell's net margin of 3.13%. Haemonetics' return on equity of 27.55% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Omnicell	3.13%	5.66%	3.57%

Haemonetics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Haemonetics presently has a consensus target price of $110.00, indicating a potential downside of 5.93%. Omnicell has a consensus target price of $57.86, indicating a potential upside of 59.21%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Haemonetics has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.99	$97.31M	$2.04	57.32
Omnicell	$1.25B	1.33	$2.05M	$0.84	43.26

In the previous week, Haemonetics had 6 more articles in the media than Omnicell. MarketBeat recorded 8 mentions for Haemonetics and 2 mentions for Omnicell. Haemonetics' average media sentiment score of 0.65 beat Omnicell's score of 0.58 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Haemonetics beats Omnicell on 11 of the 17 factors compared between the two stocks.

How does Omnicell compare to Teleflex?

Teleflex (NYSE:TFX) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Omnicell has a net margin of 3.13% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
Omnicell	3.13%	5.66%	3.57%

Teleflex presently has a consensus target price of $154.40, suggesting a potential upside of 18.34%. Omnicell has a consensus target price of $57.86, suggesting a potential upside of 59.21%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.67
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Teleflex has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

In the previous week, Omnicell had 1 more articles in the media than Teleflex. MarketBeat recorded 2 mentions for Omnicell and 1 mentions for Teleflex. Omnicell's average media sentiment score of 0.58 beat Teleflex's score of -0.15 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$2.25B	2.45	-$905.64M	-$23.29	N/A
Omnicell	$1.25B	1.33	$2.05M	$0.84	43.26

95.6% of Teleflex shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 0.7% of Teleflex shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Omnicell beats Teleflex on 12 of the 17 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.65B	$5.88B	$7.62B	$12.56B
Dividend Yield	N/A	1.74%	2.49%	28.36%
P/E Ratio	23.60	26.35	274.88	25.39
Price / Sales	1.42	81.24	622.21	97.76
Price / Cash	13.14	32.40	76.58	51.65
Price / Book	1.35	5.94	10.83	6.00
Net Income	$2.05M	$147.49M	$3.51B	$382.49M
7 Day Performance	3.20%	-0.12%	-0.20%	-1.88%
1 Month Performance	11.85%	-4.80%	-8.39%	-8.87%
1 Year Performance	21.84%	3.93%	4.15%	-5.20%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	3.4502 of 5 stars	$37.10 +2.1%	$57.86 +55.9%	+17.3%	$1.65B	$1.18B	23.60	3,580	Upcoming Earnings
AMN AMN Healthcare Services	1.5598 of 5 stars	$36.30 -0.6%	$36.50 +0.6%	+110.0%	$1.41B	$3.43B	13.54	2,664	News Coverage
WST West Pharmaceutical Services	3.9032 of 5 stars	$367.33 +0.4%	$385.33 +4.9%	+40.7%	$25.76B	$3.07B	47.03	10,800	News Coverage Upcoming Earnings Dividend Increase
MMED MiniMed Group	2.1712 of 5 stars	$18.80 -4.6%	$23.87 +27.0%	N/A	$5.55B	$3.10B	N/A	2,800	High Trading Volume
HAE Haemonetics	2.8414 of 5 stars	$121.91 +2.7%	$110.00 -9.8%	+128.4%	$5.40B	$1.35B	59.76	3,009

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 10/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, MMED, HAE, and TFX

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to MiniMed Group?

Summary

How does Omnicell compare to Haemonetics?

Summary

How does Omnicell compare to Teleflex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, MMED, HAE, and TFX

How does Omnicell compare to AMN Healthcare Services?

Do institutionals & insiders hold more shares of AMN or OMCL?

Is AMN or OMCL more profitable?

Which has preferable earnings and valuation, AMN or OMCL?

Does the media favor AMN or OMCL?

Do analysts recommend AMN or OMCL?

Which has more volatility & risk, AMN or OMCL?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Do analysts recommend WST or OMCL?

Is WST or OMCL more profitable?

Which has more volatility and risk, WST or OMCL?

Does the media favor WST or OMCL?

Do insiders and institutionals have more ownership in WST or OMCL?

Which has better earnings and valuation, WST or OMCL?

Summary

How does Omnicell compare to MiniMed Group?

Do analysts rate MMED or OMCL?

Do insiders & institutionals have more ownership in MMED or OMCL?

Is MMED or OMCL more profitable?

Does the media favor MMED or OMCL?

Which has better earnings & valuation, MMED or OMCL?

Summary

How does Omnicell compare to Haemonetics?

Is HAE or OMCL more profitable?

Which has more risk & volatility, HAE or OMCL?

Do insiders & institutionals have more ownership in HAE or OMCL?

Do analysts rate HAE or OMCL?

Which has higher valuation and earnings, HAE or OMCL?

Does the media favor HAE or OMCL?

Summary

How does Omnicell compare to Teleflex?

Is TFX or OMCL more profitable?

Do analysts recommend TFX or OMCL?

Which has more risk & volatility, TFX or OMCL?

Does the media favor TFX or OMCL?

Which has higher valuation and earnings, TFX or OMCL?

Do institutionals and insiders hold more shares of TFX or OMCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools